QDEL stock gains as QuidelOrtho beats estimates and trades near target

QuidelOrtho Corporation (ISIN US7476011036) stock is trading near analysts' average price target after the diagnostics specialist reported quarterly earnings that came in ahead of market expectations and drew fresh institutional interest as of September 4, 2026.

Earnings beat supports QDEL stock

According to a recent MarketBeat overview published on September 4, 2026, QuidelOrtho's latest quarterly earnings came in above analyst expectations, described as an earnings beat, which has helped underpin sentiment toward QDEL stock.

The same MarketBeat source notes that despite this earnings beat, QDEL opened at 13.93 dollars on September 4, 2026, which is very close to the consensus price target of 13.62 dollars compiled from covering analysts, highlighting that the upside implied by current targets is modest.

Valuation and analyst view

MarketBeat data show that QuidelOrtho presently carries an average analyst rating of Reduce, alongside that consensus price target of 13.62 dollars for QDEL stock, signaling that many analysts see limited upside from the current share price level and view the name cautiously.

With QDEL opening at 13.93 dollars on September 4, 2026, the stock is trading just 0.31 dollars above the average price target, a difference of about 2.3 percent, which is a narrow gap that suggests the market price already reflects much of the current analyst outlook on the company.

Institutional interest and diagnostics focus

The same MarketBeat alert highlights that Bank of New York Mellon Corp has recently purchased a new stake in QuidelOrtho, underscoring that some institutional investors are still willing to build positions even as the consensus rating remains cautious and the stock trades close to its targeted valuation range.

QuidelOrtho focuses on in vitro diagnostics, supplying immunoassay and molecular tests as well as clinical chemistry instruments used by hospitals and laboratories worldwide, making QDEL stock a play on demand for infectious disease testing and broader diagnostic workflows.

Representative product: Sofia rapid antigen tests

One representative product line for QuidelOrtho is its Sofia branded rapid antigen tests, which are used at the point of care for detecting respiratory infections such as influenza and other pathogens and can contribute to revenue performance when testing demand rises in specific seasons or during localized outbreaks.

QDEL stock price context

As of September 2, 2026, QDEL stock closed at 13.95 dollars on the Nasdaq, according to MarketBeat's QuidelOrtho quote page, placing the share price essentially in line with the opening level reported for September 4, 2026 and keeping it close to the 13.62 dollar consensus price target cited for the stock.